New drug combo aims to shrink brain tumors in advanced melanoma
NCT ID NCT05026983
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial is testing two oral drugs, binimetinib and encorafenib, in 35 adults with advanced melanoma that has spread to the brain. The drugs block enzymes that help cancer cells grow. The study aims to see if this combination can control the disease and improve survival, while monitoring side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- binimetinib and encorafenib
- What this could lead to
- If successful, this could offer a new treatment option for people with melanoma that has spread to the brain, potentially helping to control the disease.
- What could go wrong
- This is a small, early-phase trial with only 35 participants, so results may not apply to everyone. The drugs can cause side effects like nausea, fatigue, and vision problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Two punch of immune boosters revive cancer treatment?
- Could a personal coach at home boost energy for cancer patients?
- Morning vs. afternoon: could the clock boost immunotherapy against melanoma?
- Could a common vaccine supercharge immunotherapy against melanoma?
- Engineered immune cells take aim at Hard-to-Treat cancers
- New drug cocktail targets rare, aggressive melanoma